In a recent study, a small-molecule inhibitor of GSK3, tideglusib, reduced the mutant DMPK mRNA in myoblasts from patients with adult DM1 and congenital DM1; it also improved postnatal survival and phenotype in a DMSXL mouse model of congenital DM1 [108]. This evidence concerns the gene DMPK and myotonic dystrophy type 1.